HR+, HER2-, ADVANCED BREAST CANCER
Clinical trials for HR+, HER2-, ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+, HER2-, ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+, HER2-, ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-World data sought on ribociclib for advanced breast cancer
Disease control OngoingThis study follows 376 people with HR+HER2- advanced breast cancer in Russia to see how well ribociclib combined with hormone therapy or chemotherapy works in everyday medical practice. It does not assign treatments—doctors choose based on routine care. The main goal is to measur…
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New pill combo aims to control advanced breast cancer
Disease control OngoingThis early-stage study tests a new oral drug (SH3765) combined with fulvestrant in 30 women with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy. The main goals are to find a safe dose and check for side effects, while also measurin…
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:38 UTC
-
Real-world study tracks ribociclib in elderly breast cancer patients
Knowledge-focused OngoingThis study watches 329 older patients (65+) with HR+/HER2- advanced breast cancer who are already taking ribociclib with hormone therapy. Researchers track quality of life, treatment success, and side effects over 12 months in everyday medical practice. The goal is to learn how w…
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 17, 2026 02:08 UTC
-
Researchers to observe how well current breast cancer drugs work in everyday care
Knowledge-focused TerminatedThis study aimed to collect information from routine medical care of people with a certain type of advanced breast cancer (HR+/HER2-). Researchers planned to track side effects and how well the treatment worked, without giving any new drugs or changing care. The study was withdra…
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Sponsor: SciClone Pharmaceuticals • Aim: Knowledge-focused
Last updated May 17, 2026 02:02 UTC